The Evaluation of the Effectiveness of Cannabidiol (CBD) and Cannabinol (CBN) Oral Solutions in the Treatment of Facial Pain and Headache of Muscular Origin

The aim of the study is to evaluate the effectiveness of an aqueous solution containing CBD and CBN in the management of Facial Pain and Headache of Muscular Origin. A randomized (block randomization), double-blind, two-arm controlled trial will involve 42 adult patients diagnosed with Facial Pain and Headache of Muscular Origin which is lasting more than 3 months on the basis of clinical examination. Qualified study participants will be randomly assigned to two groups. The studied group will receive tan aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician, while the control group will receive an aqueous solution of placebo, to drink at home in the dose determined by the attending physician during this time. Each subject will be tested on the qualification day (D0), on 20 days after D0 (D20), and then 40 (D40) and 60 (D60) days after the qualification day using electromyography (EMG), pressure pain threshold test (PPT), clinical examination and surveys.

Start Date01 Apr 2025

Sponsor / Collaborator

Akademia Medyczna

NCT05344170

/ CompletedPhase 1/2IIT

A Randomised, Double-blind, Placebo-controlled, Single-dose, Crossover, Pilot Study Investigating the Effects of Cannabinol (CBN) 30 mg and 300 mg on Sleep Architecture and Next-day Function in Insomnia Disorder

This study aims to investigate the acute effects of cannabinol (CBN) 30 mg and 300 mg, versus placebo, on sleep architecture and next-day functioning in adults aged 25-65 years with chronic insomnia disorder.

Start Date24 Aug 2022

Sponsor / Collaborator

Woolcock Institute of Medical Research

[+1]

NCT05212402

/ CompletedNot ApplicableIIT

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Physiological, Biochemical, and Psychometric Impacts of a Brand-Specific Hemp-Derived Cannabidiol Product in Healthy Adults

The purpose of this prospective, randomized, double-blind, placebo-controlled trial is to assess the physiological, biochemical, and psychometric impacts of a brand-specific hemp-derived cannabidiol product in a sample of healthy adults.

Start Date18 Jan 2022

Sponsor / Collaborator

University of South Carolina

[+1]

100 Clinical Results associated with Cannabinol

100 Translational Medicine associated with Cannabinol

100 Patents (Medical) associated with Cannabinol

1,750

Literatures (Medical) associated with Cannabinol

01 Nov 2025·INTERNATIONAL JOURNAL OF DRUG POLICY

Cannabis in the wild: Analysis of street cannabis and cannabinoid composition in Australia

Article

Author: Christensen, Erynn ; Galettis, Peter ; Solowij, Nadia ; Goodwin, Isabella ; Lorenzetti, Valentina ; Gordon, Rebecca ; Chye, Yann ; Yücel, Murat ; Kirkham, Rebecca

BACKGROUND:

Australia has one of the highest rates of cannabis use globally, yet the concentration of Δ9-tetrahydrocannabinol (THC) of illicit street cannabis has not been formally assessed in over a decade. We aimed to comprehensively profile the concentration of THC, cannabidiol (CBD) and other cannabinoids in contemporary illicit street cannabis in regional Australia, assess variation over time, and examine how the amount of THC relates to consumer's perceived product strength.

METHODS:

Participants donated two 1-gram samples of cannabis at 3 different timepoints (i.e., 6 samples total) ∼9-weeks apart, over 5 months. High-performance liquid chromatography quantified the concentrations of THC, CBD, cannabigerol, cannabichromene, cannabinol, tetrahydrocannabivarin, and their plant-based carboxylic acid precursors (THCA, CBDA, CBGA, CBNA, THCVA) in percentage and milligrams.

RESULTS:

Thirty-seven participants donated 127 cannabis samples. On average, one cannabis gram contained 34.8 mg THC (6.96 Standard THC units), 12.00 % total THC (THC+(THCA*0.877)), and 0.30 % total CBD (CBD+(CBDA*0.877)). THC concentrations remained stable across participants' current and past samples over time (p > 0.05). Finally, no correlation was found between participants' subjective assessments of cannabis strength and THC or total THC content in the same product (p > 0.05).

CONCLUSIONS:

Contemporary illicit street cannabis in regional Australia is high in THC and low in CBD. The concentration of THC is lower than international trends but appears to have increased compared to reports on illicit Australian cannabis collected over 10 years ago, while low concentrations of CBD have remained stable over time. Perceived cannabis strength may be influenced by factors beyond measurable THC concentrations, such as individual tolerance, consumption methods, or consumer expectations.

01 Oct 2025·PHYTOMEDICINE

Columbianadin targets TRIM7 to maintain P2X7 palmitoylation, inhibiting cuproptosis in synovial M2 macrophages

Article

Author: Liao, Xin ; Huang, Ziyu ; Li, Zihao ; Li, Hao

BACKGROUND:

Traumatic synovitis often arises from sports injuries, and early intervention is crucial for preserving joint health. Columbianadin (CBN), a natural phytochemical, has demonstrated efficacy in inhibiting inflammatory progression through Chinese herbal injection therapy; however, its underlying mechanism remains unclear.

PURPOSE:

This study aims to investigate the molecular mechanism by which CBN maintains P2X7 palmitoylation, characterize TRIM7 as a novel cuproptosis-alert protein, and provide a theoretical foundation for the bench-to-bedside translation of CBN in treating traumatic synovitis.

METHODS:

A non-destructive anterior cruciate ligament tear model was established to induce knee joint instability in mice. TRIM7 conditional knockout mice were generated via tissue-specific gene knockout. Single-cell sequencing and bioinformatics analysis were used to screen and validate CBN targets and downstream signaling pathways. Subcellular localization changes of P2X7 were detected via fluorescence co-localization. Copper concentrations in cells and tissues were measured using inductively coupled plasma-mass spectrometry. Palmitoylation levels of P2X7 were analyzed via acyl-biotin exchange assay.

RESULTS:

CBN effectively suppressed synovial inflammation in mice. Mechanistically, CBN directly bound to TRIM7 and downregulated its expression. TRIM7 knockout significantly attenuated CBN's anti-inflammatory effects. TRIM7 competed with P2X7 for binding to ZDHHC5, leading to ubiquitination-mediated degradation of ZDHHC5. This disrupted ZDHHC5-dependent palmitoylation of P2X7, preventing its membrane localization and subsequent copper efflux. Accumulated intracellular copper induced cuproptosis.

CONCLUSION:

CBN directly targets TRIM7 to preserve ZDHHC5-mediated P2X7 palmitoylation, thereby inhibiting M2 macrophage cuproptosis in synovial tissues. These findings provide a theoretical basis for developing precision drug delivery systems targeting traumatic synovitis.

01 Oct 2025·REPRODUCTIVE TOXICOLOGY

Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation

Article

Author: Teixeira, Natércia ; Amaral, Cristina ; Sousa, Luísa G ; Fonseca, Bruno M ; Alves, Patrícia ; Correia-da-Silva, Georgina

Throughout a woman's menstrual cycle, endometrial stromal cells (ESCs) undergo cyclic morphological and functional alterations, involving proliferation, differentiation and senescence, modulated in part by steroid hormones and the endocannabinoid system. Disruptions in these processes can lead to endometrial conditions, like endometriosis or miscarriage. In this work, we examined the impact of the phytocannabinoids cannabidiol (CBD), cannabichromene (CBC), cannabidivarin (CBDV), cannabigerol (CBG) and cannabinol (CBN) at 2 µM, by using the St-T1b cell line, a representative model of ESCs. CBDV, CBD and CBN increased ESR1 transcription, while it was decreased by CBG. Estrogen receptor α (ER) protein was reduced by CBG and CBN. ER activation, assessed via TFF1 expression, was promoted by all cannabinoids except CBN, which suppressed it. Progesterone receptor gene expression increased for CBC, CBDV and CBG treatments, decreasing for CBN. Furthermore, androgen receptor (AR) transcription was upregulated by CBC and CBN, with protein levels increased only by CBN. All the cannabinoids inhibited AR activation. CBN enhanced AKT and ERK1/2 phosphorylation and upregulated AREG expression. Senescence-associated markers YPEL3 and LMNB1 were modulated by CBC, CBD, and CBN, accompanied by increased β-galactosidase accumulation. Additionally, CBC and CBD upregulated NAPE-PLD mRNA levels, the anandamide synthesis enzyme, although CBC and CBN reduced its protein expression. CBDV increased gene and protein expression of FAAH, the anandamide degrading enzyme. These results suggest that phytocannabinoids may disrupt the interplay between the endometrial endocrine signaling and the endocannabinoid system, as well as modulate senescence in ESCs, potentially affecting female fertility.

News (Medical) associated with Cannabinol

23 Sep 2025

·www.inmedpharma.com

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer’s disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026 Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer’s disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026 Vancouver, British Columbia–(Newsfile Corp. – September 23, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC (“BayMedica“). The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2025, are available at www.inmedpharma.com and at www.sedar.com. Eric A. Adams, InMed Chief Executive Officer, commented, “Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901’s potential as a small-molecule drug candidate that addresses Alzheimer’s disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer’s pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification.” Mr. Adams continued, “Looking ahead, we remain focused on advancing IND-enabling studies and generating additional data that underscore INM-901’s differentiated approach. Notably, the emphasis on neuroinflammation and multi-pathway approaches appears well aligned with the themes emerging from the recent Alzheimer’s Association International Conference (“AAIC”), where leading researchers highlighted the need to move beyond amyloid and tau pathologies alone. We believe this convergence further validates our strategy and positions InMed to contribute meaningfully to the next generation of Alzheimer’s treatments.” “Additionally, InMed has significantly strengthened its balance sheet, positioning the Company to advance its pharmaceutical development programs and deliver on key milestones into the fourth quarter of calendar year 2026.” Business Update Pharmaceutical Development Programs INM-901: Targeting several biological pathways associated with Alzheimer’s disease (“AD”) InMed’s proprietary small molecule drug candidate INM-901 continues to advance as a potential treatment for Alzheimer’s disease through its multiple mechanisms of action that target several biological pathways associated with disease progression. Throughout fiscal 2025, the Company announced several key findings for INM-901: Neuroinflammation Reported statistically significant reductions in neuroinflammation in a long-term (7-month dosing) preclinical study, including decreases in multiple plasma and brain markers of inflammation recognized as contributors to AD progression. Presented ex vivo study results showing significant reductions in neuroinflammation, including key pro-inflammatory markers, independent of amyloid beta or tau pathology. Reported statistically significant reductions in neuroinflammation in a long-term (7-month dosing) preclinical study, including decreases in multiple plasma and brain markers of inflammation recognized as contributors to AD progression. Presented ex vivo study results showing significant reductions in neuroinflammation, including key pro-inflammatory markers, independent of amyloid beta or tau pathology. Cognition & Behavioral Outcomes Demonstrated improvements in cognitive function, memory, and locomotor activity, with statistical significance achieved in certain behavioral assessments in a well-established 5xFAD AD mouse model, using a longer treatment duration and subjects with more advanced disease to validate and expand upon previous findings. These findings were presented at AAIC 2025, the world’s leading forum for Alzheimer’s disease and dementia research. Drug Delivery Confirmed INM-901 can be administered orally while achieving therapeutic brain levels comparable to intraperitoneal injection in a in vivo model, offering important advantages over routes of administration used by currently approved products. Scientific Advisory and Intellectual Property Strengthened the Company’s scientific advisory board with the appointment of Dr. Barry Greenberg, Director of the Alzheimer’s Disease Translational Center and Associate Professor of Neurology at Johns Hopkins University School of Medicine. Expanded the Company’s intellectual property with the filing of an additional international patent application under the Patent Cooperation Treaty (“PCT”), covering pharmaceutical composition and method of use for INM-901 in the treatment of neurodegenerative diseases, including Alzheimer’s disease. Strengthened the Company’s scientific advisory board with the appointment of Dr. Barry Greenberg, Director of the Alzheimer’s Disease Translational Center and Associate Professor of Neurology at Johns Hopkins University School of Medicine. Expanded the Company’s intellectual property with the filing of an additional international patent application under the Patent Cooperation Treaty (“PCT”), covering pharmaceutical composition and method of use for INM-901 in the treatment of neurodegenerative diseases, including Alzheimer’s disease. In fiscal 2026, InMed plans to develop its Alzheimer’s program, advancing Chemistry, Manufacturing, and Controls (“CMC”) activities and preparing for a pre-IND meeting and GLP-enabling studies to support an IND submission. INM-089: Neuroprotection in the treatment of dry age-related macular degeneration (“AMD”) INM-089 is a proprietary small molecule drug candidate being studied in the treatment of dry AMD. The Company continues to advance preclinical studies demonstrating significant functional and pathological improvements in a dry AMD disease study model In addition, the Company announced the selection of an intravitreal (“IVT”) formulation for INM-089, which has been successfully delivered to the targeted area of the eye in preclinical studies at doses up to 10 times the calculated safety margin relative to the intended therapeutic dose. BayMedica commercial subsidiary BayMedica, a leading supplier of non-intoxicating rare cannabinoids to the health and wellness sector, has experienced sustained revenue growth during the fiscal year 2025, reaching $4.9M, representing an 8% increase over the previous year. BayMedica continues to hold a strong competitive position in its commercial portfolio of non-intoxicating rare cannabinoids. Financial commentary: For the year ended June 30, 2025, the Company recorded a net loss of $8.2M, compared with a net loss of $7.7M for the previous year. Research and development expenses were $2.9M for year ended June 30, 2025, compared with $3.2M for the year ended June 30, 2024. However, the Company expects research and development expenses to increase significantly in future periods as it continues to advance its pharmaceutical pipeline. The Company incurred general and administrative expenses of $6.6M for the year ended June 30, 2025, compared to $5.8M in the previous year. The increase was primarily from a combination of changes including higher legal expenses, and consulting fees, offset by a decrease in office and administrative fees. The Company realized sales of $4.9M in our BayMedica segment for the year ended June 30, 2025, representing an increase of $0.34M, or 8%, as compared to the year ended June 30, 2024. As of June 30, 2025, we had cash, cash equivalents and short-term investments of $11.1M. The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026, depending on the level and timing of realizing BayMedica revenues as well as the level and timing of the Company’s operating expenses. Table 1. Consolidated Balance SheetExpressed in U.S. Dollars Table 2. Consolidated Statements of OperationsExpressed in U.S. Dollars Table 3. Consolidated Statements of Cash FlowsExpressed in U.S. Dollars About InMed InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Investor Contact:Colin ClancyVice President, Investor Relationsand Corporate CommunicationsT: +1.604.416.0999E: cclancy@inmedpharma.com Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: statements regarding InMed’s belief in the potential of INM-901 as a multi-mechanism small molecule drug candidate for Alzheimer’s disease; expectations relating to the reduction of neuroinflammation and improvements in cognition and behavior observed in preclinical studies; the ability of INM-901 to provide disease-modifying benefits independent of amyloid or tau pathologies; the advancement of chemistry, manufacturing, and controls (CMC) activities, the planning of GLP-enabling studies, and the preparation of an IND submission; the ability to achieve therapeutic brain levels through oral administration; expectations relating to intellectual property protection; the further development, potential efficacy, and marketability of INM-089 for dry age-related macular degeneration, including its neuroprotective properties and intravitreal (IVT) delivery profile; the further development and potential commercial uses of INM-755; optimism regarding alignment of the Company’s strategy with emerging industry trends and findings presented at the Alzheimer’s Association International Conference (AAIC); expectations regarding the sufficiency of the Company’s strengthened balance sheet to fund operations, advance pharmaceutical development programs, and achieve milestones into the fourth quarter of calendar year 2026; and, other business initiatives, strategies, and prospects of the Company. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267483

Financial StatementClinical Result

04 Sep 2025

·www.prnewswire.com

Charlotte's Web Announces Plans to Establish a Scientific Advisory Board

Scientific Advisory Board to Strengthen Medical Channel Strategy and Accelerate R&D Initiatives LOUISVILLE, Colo., Sept. 4, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQB: CWBHF) Charlotte's Web Holdings, Inc. (" Charlotte's Web" or the " Company"), the pioneer and market leader in hemp-derived CBD wellness, has announced the development of a Scientific Advisory Board to accelerate its medical strategy and reinforce its legacy of science-backed innovation. The board will guide the Company's research and development agenda, shape clinical initiatives, and help translate botanical science into impactful, patient-centered solutions. The Scientific Advisory Board is expected to commence work in September 2025. Founded over a decade ago with a mission to provide safe, plant-based wellness products, Charlotte's Web has consistently led the industry in research, safety, and standardization. Its origin story — centered around Charlotte Figi and the development of full-spectrum hemp genetics with naturally-occurring CBD — sparked a global movement and helped define the hemp health and wellness category. "Charlotte's Web was founded on the pillars of science, compassion, and innovation," said Bill Morachnick, CEO of Charlotte's Web. "Through our enduring partnership with the Realm of Caring , our products have been studied by leading institutions. The launch of our Scientific Advisory Board marks a pivotal step forward—deepening our commitment to expanding patient access to trusted, plant-based therapeutics." Charlotte's Web is scaling its medical channel strategy with support from its new Scientific Advisory Board, which will advise on product formulations and practitioner education and engagement. To meet rising demand for clinically relevant CBD solutions, the Company is also planning to create Continuing Medical Education (CME) content for healthcare professionals. These initiatives address a critical gap in patient care by offering practitioner-informed options for supporting the management of health issues like pain, anxiety, and problematic sleep. This initiative also strengthens its partnership with DeFloria, Inc., a collaboration including Charlotte's Web and Ajna BioSciences PBC, a botanical drug development company, focused on developing AJA001 (a full-spectrum cannabidiol (CBD) hemp extract) as a treatment for irritability associated with autism spectrum disorder. The botanical pharmaceutical candidate has received FDA approval to proceed with its planned FDA Phase 2 clinical trials. Leading the development of the Board is Dr. Marcel Bonn-Miller, Chief Scientific Officer, a world-renowned cannabinoid researcher with over 20 years of experience who has published approximately 200 research papers and is the co-inventor on multiple patents related to CBD's use in neurodevelopmental disorders. "The establishment of our Scientific Advisory Board is a critical step in advancing the clinical relevance of hemp-based therapeutics," said Dr. Marcel Bonn-Miller, Chief Scientific Officer at Charlotte's Web. "Our focus is on translating rigorous cannabinoid research into real-world solutions. By aligning scientific expertise with practitioner needs, we're helping to shape a future where plant-based medicine is both accessible and evidence-based." With this next chapter, Charlotte's Web continues to lead the evolution of cannabinoid science—bridging research, clinical practice, and patient care to set national standards in plant-based wellness. About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at . Forward-Looking Information Certain information provided herein constitutes forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are typically identified by words such as "may", "will", "should", "could", "anticipate", "expect", "project", "estimate", "forecast", "plan", "intend", "target", "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions and expected future development and other factors that it believes are appropriate and reasonable. The material factors and assumptions used to develop the forward-looking statements herein include, but are not limited to: regulatory regime changes; anticipated product development and sales; the success of sales and marketing activities; product development and production expectations; outcomes from R&D activities; the Company's ability to deal with adverse growing conditions in a timely and cost-effective manner; the availability of qualified and cost-effective human resources; compliance with contractual and regulatory obligations and requirements; availability of adequate liquidity and capital to support operations and business plans; and expectations around consumer product demand. In addition, the forward-looking statements are subject to risks and uncertainties pertaining to, among other things: supply and distribution chains; the market for the Company's products; revenue fluctuations; regulatory changes; loss of customers and retail partners; retention and availability of talent; competing products; share price volatility; loss of proprietary information; product acceptance; internet and system infrastructure functionality; information technology security; available capital to fund operations and business plans; crop risk; economic and political considerations; and including but not limited to those risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ending December 31, 2024, and other risk factors contained in other filings with the Securities and Exchange Commission available on and filings with Canadian securities regulatory authorities available at . The impact of any one risk, uncertainty, or factor on a particular forward-looking statement is not determinable with certainty, as these are interdependent, and the Company's future course of action depends on management's assessment of all information available at the relevant time. Any forward-looking statement in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable law, the Company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. All forward-looking statements, whether written or oral, attributable to the Company or persons acting on the Company's behalf, are expressly qualified in their entirety by these cautionary statements. SOURCE Charlotte's Web Holdings, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

24 Jul 2025

·www.globenewswire.com

MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This innovative product expands MediPharm’s leading CBN oil product portfolio and builds on the success of the Company’s THC Inhaler introduced earlier this year. The new metered dose inhaler delivers a precise formulation of minor cannabinoid CBN and THC in a consistent, smoke-free format. Designed for nighttime use, the product offers a fast onset experience without combustion or vapour, making it a discreet and convenient option for both consumers and medical patients. David Pidduck, CEO of MediPharm Labs, commented: "The launch of our CBN THC Metered Dose Inhaler represents a significant step forward in our strategy to deliver innovative, pharma-grade cannabinoid products globally. As international markets increasingly seek smoke-free, precisely dosed formats, MediPharm is well-positioned to lead with differentiated solutions that reflect both consumer wellness trends and medical needs. This product not only strengthens our Canadian portfolio but also supports our broader vision to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide." Key Product Highlights: Metered dose inhaler format ensures precision and repeatability for consistent outcomes.Smoke-free and vapour-free delivery with rapid onset.Familiar format similar to asthma inhalers, offering comfort and ease of use.Discreet and portable, with no lingering smell or by-products.Direct to lung delivery for higher bioavailability of CBN and THC compared to ingested formats.Available now through select Ontario adult-use retailers and nationally via the Canna Farms medical platform, with expansion to additional provinces and channels planned. The Company plans to expand their inhaler offering with additional CBD and CBG options available in the future. MediPharm Labs continues to lead in pharma-grade cannabinoid innovation, offering a diverse range of product formats tailored to the evolving needs of consumers and patients. Inhaled formats like the metered dose inhaler provide rapid onset, while other MediPharm Labs products, such as tinctures, soft chews, and soft gels offer a slower onset and longer-lasting effects. About MediPharm Labs MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products utilizing a Good Manufacturing Practices (GMP) certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities for the delivery of pure, trusted, and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company’s current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm’s reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. For further information, please contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@medipharmlabs.comWebsite: www.medipharmlabs.com Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events, or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events, or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, MediPharm’s access to and unique position in the international medical markets, MediPharm’s future growth and ability to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide, MediPharm’s timing and ability to distribute its metered dose inhalers in Canada, MediPharm’s ability to further expand its international portfolio, future growth of cannabinoid products in international markets, wellness trends and medical needs of consumers, and the success of MediPharm’s products in Canada, including MediPharm’s ability to expand distribution of its metered dose inhaler products to additional provinces and channels. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political, and social uncertainties; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14b8b11d-7c8d-4f3f-85ee-322ef92c232b

Acquisition

100 Deals associated with Cannabinol

External Link

KEGG	Wiki	ATC	Drug Bank
-	Cannabinol	-	DB14737

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epidermolysis Bullosa Dystrophica	Phase 2	France	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Dystrophica	Phase 2	Germany	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Dystrophica	Phase 2	Greece	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Dystrophica	Phase 2	Israel	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Dystrophica	Phase 2	Italy	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Simplex	Phase 2	France	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Simplex	Phase 2	Germany	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Simplex	Phase 2	Greece	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Simplex	Phase 2	Israel	InMed Pharmaceuticals, Inc.	28 Dec 2021
Epidermolysis Bullosa Simplex	Phase 2	Italy	InMed Pharmaceuticals, Inc.	28 Dec 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis